Stocks
Funds
Screener
Sectors
Watchlists
SEEL

SEEL - Seelos Therapeutics Inc Stock Price, Fair Value and News

00
Market Closed

SEEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SEEL Price Action

SEEL RSI Chart

SEEL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SEEL Valuation

SEEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SEEL Fundamentals

SEEL Revenue

SEEL Earnings

SEEL Profitability

SEEL Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.0M2.0M00
2023910.0K1.2M1.6M2.2M
2022120.0K0127.0K128.0K
202137.0K59.0K94.0K113.0K
2020392.0K409.0K38.0K45.0K
20194.4M3.1M1.7M375.0K
20165.0M5.0M8.0M5.8M
20159.7M4.7M4.1M4.8M
201407.0M7.7M9.6M
20138.2M9.4M4.5M2.5M
20124.7M5.8M6.9M7.9M
20115.2M5.3M5.0M3.6M
201003.6M4.3M5.0M
20090003.0M
SEEL
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
 CEO
 WEBSITEhttps://seelostherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES16